MEDINCELL SA (MEDCL.PA) Fundamental Analysis & Valuation

EPA:MEDCL • FR0004065605

Current stock price

22.2 EUR
+0.2 (+0.91%)
Last:

This MEDCL.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MEDCL.PA Profitability Analysis

1.1 Basic Checks

  • In the past year MEDCL has reported negative net income.
  • MEDCL had a negative operating cash flow in the past year.
  • MEDCL had negative earnings in each of the past 5 years.
  • MEDCL had negative operating cash flow in 4 of the past 5 years.
MEDCL.PA Yearly Net Income VS EBIT VS OCF VS FCFMEDCL.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M -20M -30M

1.2 Ratios

  • The Return On Assets of MEDCL (-26.75%) is worse than 78.43% of its industry peers.
Industry RankSector Rank
ROA -26.75%
ROE N/A
ROIC N/A
ROA(3y)-65.75%
ROA(5y)-56.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MEDCL.PA Yearly ROA, ROE, ROICMEDCL.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200 -300

1.3 Margins

  • Looking at the Gross Margin, with a value of 85.42%, MEDCL belongs to the top of the industry, outperforming 92.16% of the companies in the same industry.
  • MEDCL's Gross Margin has improved in the last couple of years.
  • MEDCL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.72%
GM growth 5Y7.65%
MEDCL.PA Yearly Profit, Operating, Gross MarginsMEDCL.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. MEDCL.PA Health Analysis

2.1 Basic Checks

  • MEDCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MEDCL has been increased compared to 1 year ago.
  • The number of shares outstanding for MEDCL has been increased compared to 5 years ago.
  • The debt/assets ratio for MEDCL has been reduced compared to a year ago.
MEDCL.PA Yearly Shares OutstandingMEDCL.PA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
MEDCL.PA Yearly Total Debt VS Total AssetsMEDCL.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • An Altman-Z score of 4.55 indicates that MEDCL is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of MEDCL (4.55) is better than 68.63% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 4.55
ROIC/WACCN/A
WACC7.94%
MEDCL.PA Yearly LT Debt VS Equity VS FCFMEDCL.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M

2.3 Liquidity

  • MEDCL has a Current Ratio of 2.88. This indicates that MEDCL is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 2.88, MEDCL belongs to the best of the industry, outperforming 86.27% of the companies in the same industry.
  • A Quick Ratio of 2.88 indicates that MEDCL has no problem at all paying its short term obligations.
  • MEDCL's Quick ratio of 2.88 is amongst the best of the industry. MEDCL outperforms 90.20% of its industry peers.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 2.88
MEDCL.PA Yearly Current Assets VS Current LiabilitesMEDCL.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. MEDCL.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 43.15% over the past year.
  • The Revenue has grown by 166.31% in the past year. This is a very strong growth!
  • MEDCL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 54.88% yearly.
EPS 1Y (TTM)43.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.92%
Revenue 1Y (TTM)166.31%
Revenue growth 3Y83.86%
Revenue growth 5Y54.88%
Sales Q2Q%34.66%

3.2 Future

  • MEDCL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.90% yearly.
  • MEDCL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 39.81% yearly.
EPS Next Y61.93%
EPS Next 2Y66.38%
EPS Next 3Y47.87%
EPS Next 5Y49.9%
Revenue Next Year10.51%
Revenue Next 2Y49.52%
Revenue Next 3Y66.79%
Revenue Next 5Y39.81%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
MEDCL.PA Yearly Revenue VS EstimatesMEDCL.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M 250M
MEDCL.PA Yearly EPS VS EstimatesMEDCL.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

2

4. MEDCL.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MEDCL. In the last year negative earnings were reported.
  • MEDCL is valuated quite expensively with a Price/Forward Earnings ratio of 37.81.
  • Based on the Price/Forward Earnings ratio, MEDCL is valued a bit more expensive than 64.71% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.19. MEDCL is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 37.81
MEDCL.PA Price Earnings VS Forward Price EarningsMEDCL.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MEDCL.PA Per share dataMEDCL.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • MEDCL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • MEDCL's earnings are expected to grow with 47.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y66.38%
EPS Next 3Y47.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MEDCL.PA Dividend Analysis

5.1 Amount

  • MEDCL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MEDCL.PA Fundamentals: All Metrics, Ratios and Statistics

MEDINCELL SA

EPA:MEDCL (3/27/2026, 7:00:00 PM)

22.2

+0.2 (+0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)12-09
Earnings (Next)N/A
Inst Owners32.85%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap797.20M
Revenue(TTM)28.41M
Net Income(TTM)-19.95M
Analysts85.88
Price Target34.69 (56.26%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.54%
PT rev (3m)-3.61%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)5.04%
EPS NY rev (3m)3.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 37.81
P/S 28.06
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)0.59
Fwd EY2.64%
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0.79
BVpS-0.85
TBVpS-0.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.75%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.42%
FCFM N/A
ROA(3y)-65.75%
ROA(5y)-56.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.72%
GM growth 5Y7.65%
F-Score5
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 96.28%
Cap/Sales 7.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.88
Quick Ratio 2.88
Altman-Z 4.55
F-Score5
WACC7.94%
ROIC/WACCN/A
Cap/Depr(3y)71.46%
Cap/Depr(5y)81.14%
Cap/Sales(3y)10.03%
Cap/Sales(5y)17.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.92%
EPS Next Y61.93%
EPS Next 2Y66.38%
EPS Next 3Y47.87%
EPS Next 5Y49.9%
Revenue 1Y (TTM)166.31%
Revenue growth 3Y83.86%
Revenue growth 5Y54.88%
Sales Q2Q%34.66%
Revenue Next Year10.51%
Revenue Next 2Y49.52%
Revenue Next 3Y66.79%
Revenue Next 5Y39.81%
EBIT growth 1Y49.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year78.72%
EBIT Next 3Y98.32%
EBIT Next 5Y84.38%
FCF growth 1Y21.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.67%
OCF growth 3YN/A
OCF growth 5YN/A

MEDINCELL SA / MEDCL.PA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MEDINCELL SA (MEDCL.PA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MEDCL.PA.


Can you provide the valuation status for MEDINCELL SA?

ChartMill assigns a valuation rating of 2 / 10 to MEDINCELL SA (MEDCL.PA). This can be considered as Overvalued.


What is the profitability of MEDCL stock?

MEDINCELL SA (MEDCL.PA) has a profitability rating of 1 / 10.


What is the earnings growth outlook for MEDINCELL SA?

The Earnings per Share (EPS) of MEDINCELL SA (MEDCL.PA) is expected to grow by 61.93% in the next year.